A Prospective Cohort Study Evaluating the Efficacy and Safety of Guselkumab (GUS) With JAK Inhibitors in Patients With Difficult-To-Treat Inflammatory Bowel Disease (IBD)

RECRUITING

NCT07487311

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

Summary

Patients with refractory inflammatory bowel disease (IBD) show inadequate response to conventional biologics and small molecule drugs, with persistently active disease that severely impacts quality of life and long-term prognosis. Current treatment options are limited, and the substantial disease heterogeneity makes traditional randomized controlled trials difficult to implement in this population. This study aims to explore the efficacy and safety of guselkumab (GUS) with JAK inhibitors (such as upadacitinib/tofacitinib) in this patient population, providing novel therapeutic strategies for clinical practice.

Official title: Efficacy and Safety of Guselkumab (GUS) With JAK Inhibitors in Patients With Difficult-To-Treat IBD

Key Details

Gender

All

Age Range

14 Years - 80 Years

Study Type

OBSERVATIONAL

Enrollment

80

Start Date

2026-01-07

Completion Date

2028-12-31

Last Updated

2026-03-23

Healthy Volunteers

Not specified

Conditions

Inflamatory Bowel Disease

Interventions

DRUG

guselkumab (GUS), JAK inhibitors (such as upadacitinib/tofacitinib)

Locations (1)

Center of Inflammatory Bowel Disease, Department of Gastroenterology, the Second Affiliated Hospital, Zhejiang University School of Medicine

Hangzhou, Zhejiang, China

Clinical Research Directory